Geode Capital Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.1M | Buy |
829,297
+23,112
| +3% | +$309K | ﹤0.01% | 2295 |
|
|
2025
Q1 | $8.22M | Buy |
806,185
+40,749
| +5% | +$415K | ﹤0.01% | 2412 |
|
|
2024
Q4 | $12.1M | Buy |
765,436
+39,815
| +5% | +$630K | ﹤0.01% | 2246 |
|
|
2024
Q3 | $42.1M | Buy |
725,621
+46,041
| +7% | +$2.67M | ﹤0.01% | 1529 |
|
|
2024
Q2 | $31.1M | Buy |
679,580
+83,734
| +14% | +$3.83M | ﹤0.01% | 1680 |
|
|
2024
Q1 | $39.5M | Buy |
595,846
+85,635
| +17% | +$5.67M | ﹤0.01% | 1511 |
|
|
2023
Q4 | $20.3M | Buy |
510,211
+24,210
| +5% | +$963K | ﹤0.01% | 1916 |
|
|
2023
Q3 | $15.5M | Buy |
486,001
+65,279
| +16% | +$2.08M | ﹤0.01% | 1987 |
|
|
2023
Q2 | $16.9M | Buy |
420,722
+52,676
| +14% | +$2.12M | ﹤0.01% | 1968 |
|
|
2023
Q1 | $15.7M | Buy |
368,046
+18,298
| +5% | +$781K | ﹤0.01% | 1961 |
|
|
2022
Q4 | $16.8M | Buy |
349,748
+33,599
| +11% | +$1.61M | ﹤0.01% | 1891 |
|
|
2022
Q3 | $11.9M | Buy |
316,149
+41,247
| +15% | +$1.55M | ﹤0.01% | 2110 |
|
|
2022
Q2 | $7.6M | Buy |
274,902
+59
| +0% | +$1.63K | ﹤0.01% | 2445 |
|
|
2022
Q1 | $14.9M | Buy |
274,843
+19,096
| +7% | +$1.04M | ﹤0.01% | 2078 |
|
|
2021
Q4 | $15M | Buy |
255,747
+42,941
| +20% | +$2.51M | ﹤0.01% | 2160 |
|
|
2021
Q3 | $8.42M | Sell |
212,806
-7,721
| -4% | -$305K | ﹤0.01% | 2588 |
|
|
2021
Q2 | $9.37M | Buy |
220,527
+46,506
| +27% | +$1.97M | ﹤0.01% | 2503 |
|
|
2021
Q1 | $10.7M | Buy |
174,021
+16,561
| +11% | +$1.02M | ﹤0.01% | 2319 |
|
|
2020
Q4 | $11.1M | Buy |
157,460
+47,432
| +43% | +$3.35M | ﹤0.01% | 2102 |
|
|
2020
Q3 | $4.24M | Buy |
110,028
+2,800
| +3% | +$108K | ﹤0.01% | 2489 |
|
|
2020
Q2 | $4.02M | Buy |
+107,228
| New | +$4.02M | ﹤0.01% | 2461 |
|